NCT04191148View on ClinicalTrials.gov

Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 30, 2019

Primary Completion Date

November 19, 2020

Study Completion Date

November 19, 2020

Conditions
Urinary Tract Infections
Interventions
DRUG

LBP-EC01

crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration

DRUG

Placebo

Lactated Ringers Solution for Injection dosed BID by intraurethral administration

Trial Locations (7)

29401

Ralph H. Johnson VA Medical Center, Charleston

33030

Universal Axon - Homestead, LL, Homestead

33166

Universal Axon Clinical Research, Doral

33169

AMPM Research Clinic, Miami Gardens

36207

Pinnacle Research Group, Anniston

45209

Innovation Medical Research Center, Palmetto Bay

92612

Tilda Research, Irvine

Sponsors

Lead Sponsor

Locus Biosciences
All Listed Sponsors
lead

Locus Biosciences

INDUSTRY